Who Generates More Revenue? Ascendis Pharma A/S or ACADIA Pharmaceuticals Inc.

ACADIA leads revenue race against Ascendis Pharma over a decade.

__timestampACADIA Pharmaceuticals Inc.Ascendis Pharma A/S
Wednesday, January 1, 201412000013983000
Thursday, January 1, 2015610008118000
Friday, January 1, 2016173310004606000
Sunday, January 1, 20171249010001530000
Monday, January 1, 201822380700010581000
Tuesday, January 1, 201933907600013375000
Wednesday, January 1, 20204417550006953000
Friday, January 1, 20214841450007778000
Saturday, January 1, 202251723500051174000
Sunday, January 1, 2023726437000266718000
Monday, January 1, 2024363641000
Loading chart...

Unveiling the hidden dimensions of data

Revenue Race: Ascendis Pharma A/S vs. ACADIA Pharmaceuticals Inc.

In the competitive world of pharmaceuticals, revenue generation is a key indicator of success. Over the past decade, ACADIA Pharmaceuticals Inc. has consistently outperformed Ascendis Pharma A/S in terms of revenue. From 2014 to 2023, ACADIA's revenue surged by over 6,000%, peaking at approximately $726 million in 2023. In contrast, Ascendis Pharma A/S, while showing growth, reached a maximum revenue of around $267 million in the same year.

A Decade of Growth

ACADIA's revenue growth is particularly notable between 2016 and 2023, where it increased by nearly 42 times. Ascendis Pharma A/S, despite a slower start, showed a significant leap in 2023, with a revenue increase of over 400% from the previous year. This data highlights the dynamic nature of the pharmaceutical industry and the varying growth trajectories of companies within it.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025